Objective: The aim of the study was to detect the differences in number and the distribution of angiotensin II type-1 receptor (AT1R) in BPH, high grade PIN, and adenocarcinoma of the prostate. Material & method: A prospective study was performed in RSHS, in collaboration with the Department of Anatomical Pathology. Prostate samples were taken by TUR of the prostate, and then divided into 5 groups. They were BPH, high grade PIN, adenocarcinoma of the prostate in 3 difference grades (well, moderate, and poorly differentiated). Kidney tissue for control. Immunohistochemical staining was done to determine the angiotensin II type-1 (AT1R) receptor distribution as primary antibody used was mouse monoclonal antibody AT1 (TONI-1): sc-57036, Santa Cruz Biotechnology Inc., CA. Results: Angiotensin II type-1 receptor was found in material of BPH, high grade PIN and adenocarcinoma of the prostate. The number and distribution of the receptors were not different. Conclusion: There are no significant differences in number and distribution of angiotensin II type-1 receptor on BPH, high grade PIN, and adenocarcinoma of the prostate.
Angiotensin II, high grade PIN, adenocarcinoma of the prostate
Klein E, Platz E, Thompson I. Epidemiology, etiology, and prevention of prostate cancer. Campbell – Walsh Urology. 9th ed. 2007; 90: 2866-7.
Diem T, Albert G, Melissa Sourial. Identification, distribution, and expression of angiotensin II receptors in the normal human prostate. Endocrinology 2001; 142: 1349-56.
Brunner HR, Nussberger J, Waeber B. Tissue angiotensin generation and regulation. Pharmacol Ther 2001; 65: 193-213.
Matsubara H, Inada M. Molecular insights into angiotensin II type 1 and type 2 receptors: Expression, signalling and physiologic function and clinical application. Endocrinology J 1998; 45: 137-50.
Csikos T, Chung O, Unger T. Receptors and their classification: Focus on angiotensin II and the AT2 receptor. J Hum Hypertens 1998; 12: 311-8.
Maruenda J, Bhatnagar V, Lowenthal DT. Hypertension in the elderly with coexisting benign prostatic hyperplasia. Urologie 1999; 53: 7-12.
Story DF, Ziogas J. Interaction of angiotensin II with noradrenergic transmission. Trends Pharmacol Sci 1987; 8: 269-71.
Hiroji U, Hitoshi I, Yoji N, Takeshi S. Antiproliferative activity of angiotensin II receptor blocker. Molecular Cancer Ther 2005; 4: 1699-709.
Huckle WR, Earp HS. Regulation of cell proliferation and growth by angiotensin II. Prog Growth Factor Res 1994; 5: 177-94.
Harrison-Bernard LM, Navar LG, Ho MM. Immunohistochemical localization of Ang II AT1 receptor in adult rat kidney using monoclonal antibody. Am J Physiology 1998; 273: 170-7.
Van Sande ME, Scharpe, Neels HM. Distribution of angiotensin converting enzyme in human tissue. Clin Chim Acta 1995; 147: 255-60.
Yokoyama M, Takaha M, Iwata H. Angiotensin-converting enxyme in the human prostate. Clin Chim Acta 1980; 100: 253-8.